drugset
drugset / Trial / NCT00102518

Aripiprazole Open-Label, Safety and Tolerability Study

NCT00102518 ↗

Phase 3 Completed 325 enrolled Otsuka Pharmaceutical Development & Commercialization, Inc.
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to test the long-term safety and tolerability of aripiprazole in adolescent patients with schizophrenia, and child and adolescent patients with bipolar I disorder, manic or mixed episode.

Timeline

Start
2004-09
Primary completion
2007-02
Completion
2007-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Aripiprazole Other / unclassified 2 mg Oral
Subject Aripiprazole Other / unclassified 5 mg Oral
Subject Aripiprazole Other / unclassified 10 mg Oral
Subject Aripiprazole Other / unclassified 15 mg Oral
Subject Aripiprazole Other / unclassified 20 mg Oral
Subject Aripiprazole Other / unclassified 25 mg Oral
Subject Aripiprazole Other / unclassified 30 mg Oral

Indications

bipolar I disorder schizophrenia